2021
P14.05 Phase 2, Study of Iovance Autologous Tumor Infiltrating Lymphocytes (Lifileucel, LN-144, LN-145, LN-145-S1) In Patients With Solid Tumors
Gettinger S, Kluger H, Schoenfeld A, Warner A, He K, Sukari A, Thomas S, Doger B, Lee S, Haefliger S, Goldberg Z, Cacovean A, Fiaz R, Chen G, Jagasia M, Finckenstein F, Fardis M, Jimeno A. P14.05 Phase 2, Study of Iovance Autologous Tumor Infiltrating Lymphocytes (Lifileucel, LN-144, LN-145, LN-145-S1) In Patients With Solid Tumors. Journal Of Thoracic Oncology 2021, 16: s1012-s1013. DOI: 10.1016/j.jtho.2021.08.335.Peer-Reviewed Original Research
2018
A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.
Sarnaik A, Curti B, Davar D, Kirkwood J, Hamid O, Lutzky J, Wilson M, Kluger H, Whitman E, Phan G, Thomas S, Lewis K, Arkenau H, Chesney J, Larsen B, Gorbatchevsky I, Suzuki S, Samberg N, Fardis M. A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma. Journal Of Clinical Oncology 2018, 36: tps9595-tps9595. DOI: 10.1200/jco.2018.36.15_suppl.tps9595.Peer-Reviewed Original Research